
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd has achieved its first revenue from CE-Marked Nu.Q NETs automated assay sales and has expanded evaluations to over 20 hospitals across 10 countries, indicating solid traction in the market. The company has formed strategic licensing agreements with established leaders such as Werfen and Hologic, enhancing its commercial infrastructure and potential for broader diagnostics deployment. Additionally, VolitionRX's innovative low-cost blood-based workflow and ongoing scientific advancements serve to strengthen the commercial viability and clinical appeal of its Nucleosomics platform, positioning the company favorably for future growth in human and veterinary diagnostics.
Bears say
VolitionRX Ltd faces an increased dilution risk, contributing to a negative financial outlook for the company. This heightened risk is reflected in a revised price target reduction from $5.0 to $3.0, signaling potential challenges in maintaining shareholder value. The implications of these financial adjustments underscore concerns regarding the company's ability to effectively capitalize on its Nucleosomics platform for growth amidst such risks.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares